Many cytokines and chemokines that are important for hematopoiesis activate the PI3K signaling pathway. Because this pathway is frequently mutated and activated in cancer, PI3K inhibitors have been developed for the treatment of several malignancies, and are now being tested in the clinic in combination with chemotherapy. However, the role of PI3K in adult hematopoietic stem cells (HSCs), particularly during hematopoietic stress, is still unclear. We previously showed that the individual PI3K catalytic isoforms P110α or P110β have dispensable roles in HSC function, suggesting redundancy between PI3K isoforms in HSCs. We now demonstrate that simultaneous deletion of P110α and P110δ in double knockout (DKO) HSCs uncovers their redundant requirement in HSC cycling after 5-fluorouracil (5-FU) chemotherapy administration. In contrast, DKO HSCs are still able to exit quiescence in response to other stress stimuli, such as LPS. We found that DKO HSCs and progenitors have impaired sensing of inflammatory signals ex vivo, and that levels of IL1-β and MIG are higher in the bone marrow after LPS than after 5-FU administration. Furthermore, exogenous in vivo administration of IL1-β can induce cell cycle entry of DKO HSCs. Our findings have important clinical implications for the use of PI3K inhibitors in combination with chemotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629136PMC
http://dx.doi.org/10.1172/jci.insight.125832DOI Listing

Publication Analysis

Top Keywords

dko hscs
16
hematopoietic stem
8
pi3k inhibitors
8
combination chemotherapy
8
pi3k
6
hscs
6
pi3 kinase
4
kinase alpha
4
alpha delta
4
delta promote
4

Similar Publications

Background: Humanized mice transplanted with CD34 hematopoietic cells (HPCs) are broadly used to study human immune responses and infections in vivo and for testing therapies pre-clinically. However, until now, it was not clear whether interactions between the mouse major histocompatibility complexes (MHCs) and/or the human leukocyte antigens (HLAs) were necessary for human T-cell development and immune reactivity.

Methods: We evaluated the long-term (20-week) human hematopoiesis and human T-cell development in NOD Scid Gamma (NSG) mice lacking the expression of MHC class I and II (NSG-DKO).

View Article and Find Full Text PDF
Article Synopsis
  • Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 25% of people worldwide, leading to fat buildup in liver cells, with its severe form, metabolic dysfunction-associated steatohepatitis (MASH), causing inflammation and potential liver transplants.
  • Research shows BRUCE, a liver cancer suppressor, is decreased in MASLD/MASH patients, and its role in these conditions needs further exploration, particularly in combination with the tumor suppressor PTEN.
  • In experiments with liver-specific double knockout mice (BRUCE and PTEN), BRUCE-deficient mice showed no liver disease, while the double knockout developed significant steatosis, inflammation, and fibrosis, suggesting BRUCE helps regulate mitochondrial function
View Article and Find Full Text PDF

The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression.

Exp Mol Med

August 2024

The Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Article Synopsis
  • Innate immune activation is essential for the onset of liver inflammation in nonalcoholic steatohepatitis (NASH), with unclear mechanisms of how certain immune molecules detect signals related to fat and inflammation.
  • High-fat diets trigger oxidative stress, activating specific signaling pathways (Foxo1, YAP, Notch1) in liver macrophages, while removing Foxo1 reduced inflammation and fibrosis in the liver.
  • The study reveals that the interplay between Foxo1, YAP, and Notch1 is crucial for managing lipid metabolism and immune responses during NASH, highlighting their roles as regulatory factors in disease progression.
View Article and Find Full Text PDF

Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.

Stem Cell Res Ther

July 2024

HEALIOS K.K. Kobe Research Institute, Kobe KIMEC Center Bldg. 3F, 1-5-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.

Background: The human induced pluripotent stem cells (hiPSCs) can generate all the cells composing the human body, theoretically. Therefore, hiPSCs are thought to be a candidate source of stem cells for regenerative medicine. The major challenge of allogeneic hiPSC-derived cell products is their immunogenicity.

View Article and Find Full Text PDF

The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic stem cell transplant and to treat hemoglobinapathies. Malignant cell cytoreduction is thought to occur by S-phase specific depletion of the key epigenetic regulator, DNA methyltransferase 1 (DNMT1) that, in the case of cancers, thereby releases terminal-differentiation programs. DNMT1-targeting can also elevate expression of immune function genes (HLA-DR, MICA, MICB) to stimulate graft versus leukemia effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!